Thus, chemerin/CMKLR1 may be promising new targets for the treatment of obesity and its related diseases, and peptides or other substances that affect chemerin/CMKLR1 axis will be used in the future in the treatment of obesity and diabetes [15]. This evidence concerns the gene CMKLR1 and obesity due to melanocortin 4 receptor deficiency.